Different Preparations of Tacrolimus and Medication Errors

Woywodt, Alexander; Delargy, M.; Thain, Z.

doi:10.1111/j.1600-6143.2008.02325.x

American Journal of Transplantation

2008

DOI: 10.1111/j.1600-6143.2008.02325.x

|View full text |Cite

Different Preparations of Tacrolimus and Medication Errors

Alexander Woywodt

M. Delargy²,

Z. Thain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2011

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We [ 3 ] and others [ 4 ] have previously voiced concern regarding two different formulations of Tacrolimus being available concurrently. This incident underpins our concern.…”

mentioning

confidence: 99%

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf )

Saif

Delargy

Thain

et al. 2009

Clinical Kidney Journal

View full text Add to dashboard Cite

“…We [ 3 ] and others [ 4 ] have previously voiced concern regarding two different formulations of Tacrolimus being available concurrently. This incident underpins our concern.…”

mentioning

confidence: 99%

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf )

Saif

Delargy

Thain

et al. 2009

Clinical Kidney Journal

View full text Add to dashboard Cite

Response to ‘Different Preparations of Tacrolimus and Medication Errors’

Chodoff

Hamberg²

2009

American Journal of Transplantation

View full text Add to dashboard Cite

Once- Versus Twice-Daily Tacrolimus

Barraclough

Isbel

Johnson

et al. 2011

Drugs

View full text Add to dashboard Cite

Tacrolimus is a cornerstone immunosuppressant agent in the prevention of organ rejection following transplantation. While typically administered twice daily (Prograf®), a modified-release once-daily formulation (Advagraf®) has recently been developed and licensed for use. To date, the majority of published data relating to the use of Advagraf® have arisen from industry-sponsored clinical trials. These have shown that conversion from Prograf® to Advagraf® on a 1 mg : 1 mg basis in both stable and de novo kidney and liver transplant recipients yields lower peak concentrations (C(max)) but equivalent overall drug exposure (area under the concentration-time curve from 0 to 24 hours post-dose; AUC(24)) and trough concentrations (C(min)). This has led to the proposal that the same total daily dose, target C(min) and therapeutic drug monitoring (TDM) strategies can be applied irrespective of preparation. However, while Advagraf® fulfils criteria for bioequivalence according to the European Medicines Agency and US FDA, lower tacrolimus exposure has been observed in the majority of clinical studies, particularly in the early post-transplant period. This has resulted in a need for higher doses of Advagraf® compared with Prograf® to achieve similar C(min) values. Significant between-subject variability in the C(min)/AUC(24) relationship with Advagraf® has also been demonstrated, suggesting possible problems with TDM based on C(min) values. In non-comparative conversion studies, Advagraf® demonstrated similar efficacy and safety to Prograf®. However, phase III studies in de novo kidney and liver transplant recipients have shown higher rates of acute rejection with Advagraf®, possibly explained by the differing C(max) values achieved with the two preparations. While it has been suggested that once-daily administration may improve compliance, no studies have proven this to be the case. This article reviews the pharmacokinetics, efficacy, adverse effects and utility of Advagraf® in relation to its equivalence to Prograf®, and areas that require additional research are identified.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Different Preparations of Tacrolimus and Medication Errors

Cited by 3 publications

References 3 publications

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf )

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf )

Response to ‘Different Preparations of Tacrolimus and Medication Errors’

Once- Versus Twice-Daily Tacrolimus

Contact Info

Product

Resources

About